Abstract
Own experience uses Janus kinase inhibitors 1 type (Ranvek) in a patient with seronegative RA. Clinical observation
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
https://doi.org/10.36361/18148999_2022_23_3_150
Publication Date: Jan 1, 2022 |
Own experience uses Janus kinase inhibitors 1 type (Ranvek) in a patient with seronegative RA. Clinical observation
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.